Course and clinical severity of the SARS-CoV-2 Omicron variant infection in Tianjin, China

Yi Ren[1,2,†], Lixia Shi[1,2,†], Yi Xie[1,2], Chao Wang[1,2], Wenxin Zhang[1,2], Feifei Wang[1,2], Haibai Sun[1,2], Lijun Huang[1,2], Yuanrong Wu[1,2], Zhiheng Xing[1,2], Wenjuan Ren[1,2], Joachim Heinrich[3,4], Qi Wu[2,5], Zhengcun Pei[5*]

Affiliations:

[1] Haihe Hospital, Tianjin University, Tianjin, China

[2] Tianjin Institute of Respiratory Diseases, Tianjin, China

[3] Institute and Clinic for Occupational, Social and Environmental Medicine, University Hospital, Ludwig Maximilians University Munich, Munich, Germany

[4] Allergy and Lung Health Unit, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia

[5] Medical college, Tianjin University, Tianjin, China

[†]These first authors contributed equally to this article.

[*]Corresponding author

Prof. Zhengcun Pei

Mailing address:

No.92 Weijin Road, Nankai District, Tianjin, 300072, China

Medical college, Tianjin University

Telephone Number: 86-22-83612122

Email: peizhengcun@tju.edu.cn

Word Count for abstract and text: 143 and 2735

Abstract

There is limited information describing the course and severity of illness in subjects infected by the SARS-CoV-2 Omicron variant, especially in children. In this population-based cohort study, subjects with Omicron variant infection during the outbreak between January 8 and February 12, 2022 in Tianjin, China were included. The main outcomes were the distribution of illness severity and clinical courses. Of the 429 subjects (113 [26.3%] children; 239 [55.7%] female; median age, 36 years [IQR 15.0 to 55.0 years]), the proportion (95% CI) of symptomatic subjects on admission was 95.6% (93.2%, 97.2%), including 60.4% (55.7%, 64.9%) mild, 35.0% (30.6%, 39.6%) moderate, and 0.2% (0.0%, 1.3%) severe. Compared with adults, children had lower proportion of moderate Covid-19 (8.8% vs 44.3%). The median (IQR) length of hospital stay was 14.0 (12.0, 15.0) days. Symptomatic and moderate Covid-19 in Omicron infections was common in adults and children.

Keywords: SARS-Cov-2, Omicron, course, illness severity, children

Introduction

Omicron, the fifth severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concern (VoC) [1], has become the dominant variant in many countries since first sequenced in November 2021. On January 8, 2022, the first laboratory-confirmed Omicron case in mainland China emerged in Tianjin after a successful null COVID strategy in China. Soon after, over 400 Omicron-infected patients were identified through 4 rounds of whole-population screening of approximately 14 million inhabitants. As of February 12, 2022, nearly 90% of the cases had recovered and discharged from the designated hospital.

Limited information has been available to describe the severity and the course of illness in patients infected by the Omicron variant, especially in children. Reduced illness severity of Omicron infection has been reported in South Africa, England and Canada [2-5], however, the policy of Covid-19 control and prevention, population demographics, extend of previous infection, vaccination characteristics are substantially different in China.

This study describes the illness severity and course of SARS-CoV-2 Omicron infection in a large general population of children and adults residing in the metropolitan area of Tianjin, using data of all identified infected subjects during the outbreak.

Materials and methods

Study design and population

This population-based cohort study was conducted in Tianjin, where the first Omicron outbreak in China took place. The metropolitan area of Tianjin has a population size of 14 million. Since the identification of the first patient with Omicron infection on January 8, 2022, Tianjin instituted a fast and comprehensive testing policy, where 4 rounds of whole-

population screening were conducted to identify persons with positive result on polymerase chain reaction (PCR) testing of a nasopharyngeal or pharyngeal swab sample. As of January 21, 2022, the total number of PCR tests exceeded 58 million and all inhabitants were tested at least once (Figure 1). The positive tested subjects were transferred to and monitored at Haihe Hospital, the only designated hospital for Covid-19 patients in Tianjin. Persons who had close contact with the positive tested subjects for 2 days before the occurrence of symptoms, or 2 days before the sampling of asymptomatic infected subjects, were transferred to designated hotels and started a 14-day quarantine thereafter. They were retested every day and were transferred to hospital if they got a positive test result, or sent back home if they remained test negative by the end of quarantine. All Omicron infections were finally confirmed by Chinese center for disease control and prevention with whole genome sequencing. In total, 429 consecutive, all positive tested subjects admitted between January 8 and February 12, 2022, including children and adults, were included in this analysis.

Subjects below 18 years were labeled as "children" in the present texts. This study was approved by the institutional review board at Haihe Hospital (Approval number: 2022HHWZ-002), the written informed consent was waived owing to the use of retrospective data.

Study outcomes and data collection

The primary outcome of interest was illness severity and its progression during hospital stay, including asymptomatic, mild, moderate, and severe patients at admission to hospital and at discharge. Several clinical course-related time intervals were used as secondary outcomes, including the interval from hospital admission to the onset of Covid-19 symptoms in

presymptomatic patients; the interval from hospital admission to aggravation (including development of new symptoms or worsen of preexisting symptoms) or relief of symptoms for the first time in symptomatic patients, and the interval of reversing positive PCR-test into negative, and length of hospital stay of all patients.

Illness severity was defined by clinical physicians based on the latest version of Chinese guidelines for the diagnosis and treatment of Covid-19 [6], which is highly consistent with the World Health Organization criteria [7]. Briefly, mild disease was defined as presenting mild symptoms, including fever, cough, sore throat, sputum, runny nose, myalgias, etc., but without evidence of viral pneumonia or hypoxia. Moderate disease was defined as having non-severe signs of pneumonia, such as fever, cough, dyspnea, fast breathing, chest indrawing, etc. In addition, moderate disease was distinguished from mild disease assisted with chest Computed Tomography (CT) by confirming the appearance of pneumonia, such as ground-glass opacity, nodular lesion, consolidation, infiltration, etc. Presymptomatic was defined as being asymptomatic on admission but developed symptoms during hospital stay. Vaccination status was defined as unvaccinated, partially vaccinated (one dose), fully vaccinated (two doses) or booster vaccinated (two priming doses plus a booster dose). The inhabitants of Tianjin received exclusively inactivated vaccines, namely BBIBP-CorV [8] or CoronaVac [9,10], which were manufactured in China. Both vaccines were approved as highly effective against symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 [11,12]. Information on demographic characteristics, comorbidities (i.e. cardiovascular disease, diabetes, endocrine disorder, respiratory disease, and tumor), clinical features, radiographical appearances were extracted from patients' electronic medical record,

and the intervals from admission to specific events were manually calculated by via medical record review.

Statistical analysis

Analyses were stratified by age (children: < 18 years vs adults: ≥ 18 years), or by illness severity status on admission and discharge diagnosis (moderate vs mild) to compare the differences between groups. Asymptomatic and severe diseases were excluded from some analyses because of small numbers in subgroups.

Continuous variables included in the present analyses were not normally distributed, thus data were described with median (interquartile range, IQR), and categorical variables with n (%). The distribution of illness severity was described with proportions (95% confidence interval, 95%CI). Continuous variables were compared between groups using Mann-Whitney U test or Kruskal-Wallis test, as appropriate. Categorical variables were compared using a χ^2 test or Fisher's exact test, as appropriate. Multivariable logistic and linear regression models were used to calculate crude and adjusted odds ratios (OR) or β-coefficients and their 95% CIs for the associations between illness severity, or course intervals and their influencing factors, including age group (<18 years vs ≥ 18 years), sex, BMI, vaccination status, smoking, and comorbidities of cardiovascular diseases and diabetes, etc. Illness severity was additionally adjusted for the course interval models. The categories of unvaccinated and partially vaccinated were combined as reference because of small numbers. A 5% significance level (2-sided) was used. Analysis was performed using version 4.1.2 of the R programming language (R Project for Statistical Computing; R Foundation).

Results

Clinical characteristics of study population

A total of 429 patients were included (median age 36.0 years; IQR 15.0 to 55.0; range 0 to 90 years; 55.7% female), 113 (26.3%) were children (median age 10.0 years; IQR 8.0 to 11.0; 51.3% female) and 316 (73.7%) were adults (median age 47.0 years; IQR 34.0 to 58.0; 51.3% female) (Table 1). Eighty out of 113 (70.8%) children had received two doses of vaccines and only one child had received a booster injection, while 106 (33.5%) and 142 (44.9%) adults had received two or three doses. Children had fewer comorbidities (2.7% vs 32.0%, p<0.001) and fewer abnormal lung findings in chest CT on admission (47.8% vs 84.8%, p<0.001) as compared with adults. As of the present analyses, there were still 44 (10.3%) patients hospitalized (3 children and 41 adults).

The most common symptoms in children and adults were fever and cough, followed with sputum and sore throat without differences (Table 2 in the Supplement). Half of children with moderate Covid-19 had runny nose, which was higher than that for adults (50.0% vs 5.7%, p < 0.001). Within the mild Covid-19 group, the proportion of abnormal CT findings on admission in children were lower than that in adults, with the exception of infiltration; while within the moderate group, there were no major differences between the two groups. On discharge, children who experienced moderate Covid-19 had higher proportion of lateral abnormal CT findings than that for adults (50.0% vs 12.1%, p = 0.007).

Illness severity of the SARS-CoV-2 Omicron variant

On admission, 19 out of 429 subjects (4.4% [95%CI: 2.9%, 6.8%]) were asymptomatic and 95.6% (93.2%, 97.2%) were symptomatic and developed at least a mild course, including 60.4% (55.7%, 64.9%) mild, 35.0% (30.6%, 39.6%) moderate, and 0.2% (0.0%, 1.3%) severe

(Table 3), whereas 45.9% (41.3%, 50.7%) of the subjects were diagnosed as having

experienced mild Covid-19 on discharge, 42.2% (37.6%, 46.9%) experienced moderate

Covid-19. During the hospital stay, 6 (1.4% [0.6%, 3.0%]) subjects remained asymptomatic.

Compared with adults, children had higher proportions of asymptomatic (9.7% vs 2.5%, p =

0.003) and mild Covid-19 (81.4% vs 52.8%, p < 0.001), and lower proportion of moderate

Covid-19 (8.8% vs 44.3%, p < 0.001) on admission. On discharge, children had milder illness

severities as compared with adults.

Compared with children, adults were more likely to have moderate Covid-19 than mild on

admission (odds ratio [OR]: 4.95, 95%CI: 2.20, 11.97) (Table 4), and were more likely to

experience moderate than mild during hospital stay (OR: 7.95, 95%CI: 3.68, 18.23). In adults,

the OR for age and illness severity (moderate vs mild) was 1.04 (95% CI: 1.02,1.06) on

admission and 1.05 (95% CI: 1.02, 1.07) on discharge. BMI was positively associated with

illness severity in discharge diagnosis (OR, 1.08, 95%CI: 1.01, 1.16).

Course of the SARS-CoV-2 Omicron Variant

The median length of hospital stay was 14.0 (IQR: 12.0, 15.0) days for all patients, there was

no difference between children and adults (median: 13.5, IQR: 12.0, 15.0 and median: 14.0,

IQR: 12.0, 16.0, p = 0.21) (Figure 2).   The median interval of reversing positive PCR-test

into negative was 12.0 (10.0, 13.0) days. The median interval from hospital admission to the

onset of Covid-19-relevant symptoms in presymptomatic patients was 4.0 (2.0, 5.0) days; the

median intervals from hospital admission to aggravation of symptoms for patients with mild

and moderate were 3.0 (2.0, 5.0) days and 4.0 (3.0, 5.0) days, respectively. The median

intervals from hospital admission to relief of symptoms for presymptomatic, mild and

moderate severity were 9.0 (8.0, 10.0), 5.0 (3.0, 6.0) and 5.0 (4.0, 7.0) days, respectively.

Compared with unvaccinated or partially vaccinated patients, adults who received three doses

of vaccines had shorter interval of reversing positive PCR-test into negative (β: -1.59, 95%CI:

-2.99, -0.20) (Table 5). Children with moderate illness on admission were more likely to have

delayed aggravation of Covid-19 symptoms (β: 2.72, 95%CI: 0.11, 5.32). In adults, BMI and

cardiovascular disease were associated with higher odds of aggravation of Covid-19

symptoms (OR: 1.06, 95%CI: 1.00, 1.13; and OR: 2.18, 95%CI: 1.07, 4.52, respectively)

(Table 6 in the Supplement).

Discussion

To our knowledge, this study reports the first population-based cohort of Omicron outbreak in

China. CT-confirmed moderate Covid-19 had an overall prevalence of 35.0% on admission

and 42.2% during hospital stay. The prevalence of moderate COVID-19 on admission and

during hospital stay in children was 8.8% and 10.6%, whilst in adults 44.3% and 53.5%,

respectively.   The median length of hospital stay was 14.0 (IQR: 12.0, 15.0) days for all

patients and the median interval of reversing positive PCR-test into negative was 12.0 (10.0,

13.0) days.

Comparisons with other study findings

The situation in China and more specifically in Tianjin is different from the settings of many,

maybe all settings of other papers in several aspects: Null COVID strategy in China, Chinese

vaccine, whole population screening, strict quarantine, and strict nonpharmaceutical

interventions (NPIs). Apart from keeping social distance, wearing masks, reducing public

gatherings, additional NPIs in China included verification of health codes and travel record

card (which were embedded on mobile phone apps) at all entrances of public buildings, and transformation from offline to online activities (teaching, meeting, etc.). This makes a direct comparison with other study findings difficult. Moreover, these study findings cannot compare with any other outbreak study with Omicron SARS-CoV-2 in China, because of the uniqueness of the outbreak in Tianjin. Therefore, the following comparisons with other study results are limited and needs a cautious interpretation.

Study setting and course findings

The prevention and control of Covid-19 in China has been conducted on an ongoing basis since April 29, 2020, after the last hospitalized Covid-19 patient in Wuhan was discharged [13]. Afterwards, China has strictly adopted dynamic and targeted approaches all over the country to ensure early detection, quick response, targeted prevention and control, and effective treatment against Covid-19 [13], known as null-Covid strategy. This strategy ensured the fast tracing of all individuals who were infected by the Omicron variant and their close contacts, followed with strict quarantine and regular monitor to reduce further transmission. And this provided the possibility to calculate the course intervals using positive PCR-test, mostly the same day with hospital admission, as a beginning, which was unable to achieve in most previous studies. We found that the time intervals of reversing positive PCR-test into negative and the lengths of hospital stay were similar among different illness severity groups, which was probably a result of comprehensive interventions and treatments during hospital stay. These results need to be understood and interpreted cautiously. Based on our results, the time needed for reversing positive PCR-test into negative might be 2 weeks or longer in patients with Omicron infection, assuming the interventions or treatments were

effective.

Illness severity findings

Our results show a high prevalence of moderate Covid-19, while previous studies have focused more on the hospital admission rate, proportion of severe, critical and fatal diseases and demonstrated that Omicron patients were more likely to be mild, less hospitalized, less severe disease, and of lower mortality in South Africa [2,3], these findings were confirmed with data from Canada [4] and England [5]. In our study, the Omicron infection was most likely to be mild (over 50%) with no fatal cases observed, however, the proportion of moderate Covid-19 should not be neglected. It is plausible that the possibility of developing long-term sequelae of COVID-19 would be higher in moderate than in mild patients, which is in particular important for children. The intrinsic virulence of omicron may be not as mild as observed.

Protective effect of vaccination

Covid-19 vaccines, in particular with a booster dose, has been reported associated with less infections [14], less severe illness [15,16], lower likelihood of being symptomatic [17], but the protection effect may wane with time [14] and be weakened via immune escape [18,19] and confounded by different levels of herd immunity. Notably, COVID-19 vaccines for children are currently unavailable or not yet offered in most countries [20], which leaves children more vulnerable to Omicron. In addition, previous infection of Covid-19 may also help build acquired immunity [21]. In the present study, nearly 80% of the study population received two or three doses of Chinese inactivated vaccines, and none of the patients had prior Covid-19 infection. The inactivated vaccines are different from mRNA vaccines in

nature, which may result in different effectiveness against the Omicron variant, as none of them were initially designed for this variant, thus direct comparisons between our study and others were inappropriate. Although preexisting acquired or natural immunity normally plays an important role [22, 23], it is noteworthy to mention that the patients in our study were monitored in hospital since they were tested positive, preventive medicine and treatments according to symptoms were available for all patients, which might have also played an important role in reducing illness severity.

Strengths and limitations

This study has several strengths, which are summarized as followed: This is an almost complete whole population study of the entire inhabitants of Tianjin, which allows a quantitative evaluation of disease courses and disease progression of SARS-CoV-2 Omicron infection. The present study traced all patients of the outbreak and included detailed information on clinical course started early since positive nucleic acid tests. Moreover, data on children have been insufficiently described in previous studies. A third strength owes to the use of CT scans to confirm the diagnosis of moderate disease.

This study also has several limitations. First, due to the unique characteristics of the setting of this study, the results might be presumably similar in other regions of China, but not in other parts of the world. Thus, this study has a limited generalizability, because the study population received inactivated vaccines, where mRNA vaccines were used in most of the settings of other publications. Second, adjustment for potential confounders were not applicable due to small numbers or low prevalence in children, although stratification analyses were conducted. Third, following the regulations of null-Covid strategy in China, all

patients in the present study were hospitalized as opposed to most other populations in the world, the results may not correlate as well to other populations. However, this setting strengthens our confidence of describing real-world distribution of disease severity, as recruiting all positive patients is infeasible in most cases.

In conclusion, symptomatic Covid-19 was predominant in the Omicron outbreak in Tianjin, with high prevalence of moderate Covid-19 in adults and children. The course from positive PCR-test to negative took approximately 2 weeks. The findings suggest that moderate course of Covid-19 had unexpectedly higher proportion in the entire patient population, which is important in light of the current epidemic in China.

Author Contributions: Zhengcun Pei had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Yi Ren and Lixia Shi contributed equally to this article.

Concept and design: Zhengcun Pei, Yi Ren, Lixia Shi, Qi Wu

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Zhengcun Pei, Yi Ren, Lixia Shi

Critical revision of the manuscript for important intellectual content: All authors

Statistical analysis: Zhengcun Pei

Data collection: Yi Xie, Chao Wang, Wenxin Zhang, Feifei Wang, Haibai Sun, Lijun Huang, Yuanrong Wu, Zhiheng Xing, Wenjuan Ren

Data Availability: The data underlying this article cannot be shared publicly for the privacy of individuals that participated in the study. The data will be shared on reasonable request to the corresponding author.

Supplementary data: Supplementary data are available at IJE online.

Funding: None.

Disclosure statement: The authors report there are no competing interests to declare.

References

1. WHO. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. Geneva: WHO. 2021. Accessed February 12, 2022. https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern.

2. Maslo C, Friedland R, Toubkin M, Laubscher A, Akaloo T, Kama B. Characteristics and Outcomes of Hospitalized Patients in South Africa During the COVID-19 Omicron Wave Compared With Previous Waves. JAMA. 2022;327(6):583-584.

3. Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. Lancet. 2022;399(10323):437-446.

4. Ulloa AC, Buchan SA, Daneman N, Brown KA. Estimates of SARS-CoV-2 Omicron Variant Severity in Ontario, Canada. JAMA.2022; published online Feb 17. https://10.1001/jama.2022.2274.

5. UK Health Security Agency. SARS-CoV-2 variants of concern and variants under investigation in England. Technical briefing: update on hospitalisation and vaccine effectiveness for omicron VOC-21NOV-01 (B.1.1.529). 2021. Accessed February 12, 2022. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1044481/Technical-Briefing-31-Dec-2021-Omicron_severity_update.pdf.

6. China National Health Commission. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 8). 2021. Accessed February 12, 2022. http://www.gov.cn/zhengce/zhengceku/2021-04/15/content_5599795.htm. (In Chinese).

7. WHO. Clinical management of COVID-19. 2020. Accessed February 12, 2022. https://www.who.int/publications-detail-redirect/clinical-management-of-covid-19.

8. Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2

trial. Lancet Infect Dis. 2021;21(1):39-51.

9. Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(2):181-192.

10. Wu Z, Hu Y, Xu M, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(6):803-812.

11. Zeng G, Wu Q, Pan H, et al. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. Lancet Infect Dis. 2021; published online Dec 7. https://10.1016/S1473-3099(21)00681-2.

12. Wu D, Zhang Y, Tang L, et al. Effectiveness of Inactivated COVID-19 Vaccines Against Symptomatic, Pneumonia, and Severe Disease Caused by the Delta Variant: Real World Study and Evidence — China, 2021. China CDC Wkly. 2022;4(4):57-65.

13. The State Council Information Office of China. Fighting Covid-19: China in Action. 2020. Accessed February 12, 2022. http://www.scio.gov.cn/zfbps/32832/Document/1681809/1681809.htm.

14. Hall V, Foulkes S, Insalata F, et al. Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection. N Engl J Med. 2022; published online Feb 16. https://2022.10.1056/NEJMoa2118691.

15. Modes ME, Directo MP, Melgar M, et al. Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022. MMWR Morb

Mortal Wkly Rep. 2022;71(6):217-223.

16. Kuhlmann C, Mayer CK, Claassen M, et al. Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose. Lancet. 2022;399(10325):625-626.

17. Accorsi EK, Britton A, Fleming-Dutra KE, et al. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. JAMA. 2022; published online Feb 15. https://10.1001/jama.2022.0470.

18. Pajon R, Doria-Rose NA. SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination. N Engl J Med. 2022; published online Jan 26. https://10.1056/NEJMc2119912.

19. Rössler A, Riepler L, Bante D, von Laer D, Kimpel J. SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons. N Engl J Med. 2022;386(7):698-700.

20. Kozlov M. Does Omicron hit kids harder? Scientists are trying to find out. Nature. 2022; published online Feb 4. https://10.1038/d41586-022-00309-x.

21. Altarawneh HN, Chemaitelly H, Hasan MR, Ayoub HH. Protection against the Omicron Variant from Previous SARS-CoV-2 Infection. N Engl J Med. 2022; published online Feb 9. https://10.1056/NEJMc2200133.

22. Nealon J, Cowling BJ. Omicron severity: milder but not mild. Lancet. 2022;399(10323):412-413.

23. Bhattacharyya RP, Hanage WP. Challenges in Inferring Intrinsic Severity of the SARS-CoV-2 Omicron Variant. N Engl J Med. 2022; published online Feb 17. https://10.1056/NEJMp2119682.

Table 1. Demographic and radiographical findings of subjects with Omicron infection, by age

	Overall (n=429)	Children (n=113)	Adults (n=316)	p-value
Age, years	36.0 (15.0, 55.0)	10.0 (8.0, 11.0)	47.0 (34.0, 58.0)	<0.001
Sex				0.274
Male	190 (44.3)	55 (48.7)	135 (42.7)	
Female	239 (55.7)	58 (51.3)	181 (57.3)	
Weight, kg	65.0 (52.0, 77.0)	36.0 (25.50, 51)	70.0 (60, 80)	<0.001
Height, cm	162.0 (155.0, 170.0)	145.0 (130.5, 157.5)	167.0 (160.0, 172.0)	<0.001
BMI, kg/m^2	24.0 (20.5, 27.3)	18.0 (15.4, 22.043)	25.4 (22.4, 28.1)	<0.001
Vaccination status				0.009
Unvaccinated	22 (5.1)	9 (8.0)	13 (4.1)	0.135
Partially vaccinated	23 (5.4)	6 (5.3)	17 (5.4)	1.000
Fully vaccinated	186 (43.4)	80 (70.8)	106 (33.5)	<0.001
Booster vaccinated	143 (33.3)	1 (0.9)	142 (44.9)	<0.001
Unknown	55 (12.8)	17 (15.0)	38 (12.0)	0.415
Current or former smoker	38 (8.9)	0 (0.0)	38 (12.0)	-
Comorbidities				
Any	104 (24.2)	3 (2.7)	101 (32.0)	<0.001
Cardiovascular disease	89 (20.7)	2 (1.8)	87 (27.5)	<0.001
Endocrine disorder	5 (1.2)	0 (0.0)	5 (1.6)	-
Diabetes	31 (7.2)	1 (0.9)	30 (9.5)	0.001

Respiratory disease	7 (1.6)	0 (0.0)	7 (2.2)	-
Tumor	2 (0.5)	0 (0.0)	2 (0.6)	-
Computed Tomography findings on admission				
Any abnormal lung findings	322 (75.1)	54 (47.8)	268 (84.8)	<0.001
Lateral	121 (28.2)	27 (23.9)	94 (29.7)	0.240
Bilateral	190 (44.3)	20 (17.7)	170 (53.8)	<0.001
Ground-glass opacities	144 (33.6)	13 (11.5)	131 (41.5)	<0.001
Consolidation	6 (1.4)	0 (0.0)	6 (1.9)	-
Nodular lesion	193 (45.0)	32 (28.3)	161 (50.9)	<0.001
Infiltration	67 (15.6)	10 (8.8)	57 (18.0)	0.031

[a] Asymptomatic at discharge denotes being asymptomatic during the entire hospital stay

[b] Symptomatic at discharge included patients who were symptomatic or presymptomatic on admission

Data are median (IQR) or n (%). p values were calculated by Mann-Whitney U test, Kruskal-Wallis test, χ^2 test, or Fisher's exact test, as appropriate. χ^2 test comparing all subcategories.

Table 2. Clinical and radiographical findings in mild and moderate Omicron infections, by age

	Mild (n=259)			Moderate (n=150)		
	Children (n=92)	Adults (n=167)	p-value	Children (n=10)	Adults (n=140)	p-value
Symptoms on admission						
Any	77 (83.7)	137 (82.0)	0.736	9 (90.0)	103 (73.6)	0.453
Sore throat	15 (16.3)	37 (22.2)	0.336	1 (10.0)	28 (20.0)	0.688
Fever	44 (47.8)	60 (35.9)	0.062	6 (60.0)	49 (35.0)	0.172
Headache	5 (5.4)	6 (3.6)	0.528	0 (0)	6 (4.3)	-
Cough	38 (41.3)	74 (44.3)	0.640	7 (70.0)	67 (47.9)	0.305
Sputum	9 (9.8)	28 (16.8)	0.177	2 (20.0)	32 (22.9)	1.000
Dyspnoea	0 (0)	2 (1.2)	-	0 (0)	1 (0.7)	-
Tachypnoea	0 (0)	1 (0.6)	-	0 (0)	1 (0.7)	-
Runny nose	14 (15.2)	14 (8.4)	0.137	5 (50.0)	8 (5.7)	<0.001
Myalgia	1 (1.1)	11 (6.6)	0.061	0 (0)	5 (3.6)	-
Fatigue	5 (5.4)	19 (11.4)	0.124	0 (0)	6 (4.3)	-
Loss of taste	0 (0)	1 (0.6)	-	0 (0)	1 (0.7)	-
Loss of smell	0 (0)	1 (0.6)	-	0 (0)	1 (0.7)	-
Malaise	1 (1.1)	0 (0)	-	0 (0)	1 (0.7)	-
Diarrhoea	1 (1.1)	8 (4.8)	0.165	0 (0)	1 (0.7)	-

Symptoms on discharge

Any	3 (3.3)	10 (6.0)	0.391	1 (10.0)	10 (7.1)	0.545
Sore throat	0 (0)	1 (0.6)	-	0 (0)	0 (0)	-
Fever	1 (1.1)	1 (0.6)	1.000	0 (0)	1 (0.7)	-
Headache	0 (0)	0 (0)	-	0 (0)	0 (0)	-
Cough	2 (2.2)	7 (4.2)	0.490	1 (10.0)	8 (5.7)	0.537
Sputum	0 (0)	3 (1.8)	-	1 (10.0)	5 (3.6)	0.398
Dyspnoea	0 (0)	0 (0)	-	0 (0)	0 (0)	-
Tachypnoea	0 (0)	0 (0)	-	0 (0)	1 (0.7)	-
Runny nose	0 (0)	0 (0)	-	0 (0)	1 (0.7)	-
Myalgia	0 (0)	0 (0)	-	0 (0)	0 (0)	-
Fatigue	0 (0)	0 (0)	-	0 (0)	0 (0)	-
Loss of taste	0 (0)	0 (0)	-	0 (0)	0 (0)	-
Loss of smell	0 (0)	0 (0)	-	0 (0)	0 (0)	-
Malaise	0 (0)	0 (0)	-	0 (0)	0 (0)	-
Diarrhoea	0 (0)	0 (0)	-	0 (0)	0 (0)	-

Computed Tomography findings on

admission

Any abnormal findings	41 (44.6)	127 (76.0)	<0.001	8 (80.0)	137 (97.9)	0.036
Lateral	20 (21.7)	58 (34.7)	0.028	4 (40.0)	35 (25.0)	0.502
Bilateral	13 (14.1)	65 (38.9)	<0.00	4 (40.0)	100 (71.4)	0.084

1						
Ground-glass opacities	6 (6.5)	39 (23.4)	0.001	7 (70.0)	92 (65.7)	1.000
Consolidation	0 (0)	1 (0.6)	-	0 (0)	5 (3.6)	-
Nodular lesion	25 (27.2)	73 (43.7)	0.008	2 (20.0)	83 (59.3)	0.315
Infiltration	6 (6.5)	17 (10.2)	0.321	3 (30.0)	38 (27.1)	1.000
Computed Tomography findings on discharge						
Any abnormal findings	41 (44.6)	127 (76.0)	<0.001	9 (90.0)	104 (74.3)	0.452
Lateral	8 (8.7)	37 (22.2)	0.055	5 (50.0)	17 (12.1)	0.007
Bilateral	6 (6.5)	76 (45.5)	<0.001	4 (40.0)	85 (60.7)	0.325
Ground-glass opacities	2 (2.2)	46 (27.5)	<0.001	8 (80.0)	67 (47.9)	0.106
Consolidation	0 (0)	7 (4.2)	-	0 (0)	3 (2.1)	-
Nodular lesion	11 (12.0)	59 (35.3)	0.003	3 (30.0)	72 (51.4)	0.315
Infiltration	0 (0)	24 (14.4)	-	3 (30.0)	33 (23.6)	0.705

Patients who were categorized as asymptomatic were excluded in this table because some of them were presymptomatic (n=13), and severe patients were also excluded because of small number (n=1).

Data are n (%). p values were calculated by Mann-Whitney U test, Kruskal-Wallis test, χ^2 test, or Fisher's exact test, as appropriate.

Table 3. Distribution of illness severity of persons infected with the SARS-CoV-2 Omicron variant

	Persons, No. (%) [95%CI]			p-value[b]
	All patients n=429)	Age < 18 years (n=113)	Age ≥ 18 years (n=316)	
Illness severity status on admission				
Asymptomatic	19 (4.4) [2.9, 6.8]	11 (9.7) [5.5, 16.6]	8 (2.5) [1.3, 4.9]	0.003
Mild	259 (60.4) [55.7, 64.9]	92 (81.4) [73.3, 87.5]	167 (52.8) [47.3, 58.3]	<0.001
Moderate	150 (35.0) [30.6, 39.6]	10 (8.8) [4.9, 15.5]	140 (44.3) [38.9, 49.8]	<0.001
Severe	1 (0.2) [0.0, 1.3]	0 (0.0)	1 (0.3) [0.1, 1.8]	-
Discharge diagnosis				
Asymptomatic[a]	6 (1.4) [0.6, 3.0]	5 (4.4) [1.9, 9.9]	1 (0.3) [0.1, 1.8]	0.006
Mild	197 (45.9) [41.3, 50.7]	93 (82.3) [74.2, 88.2]	104 (32.9) [28.0, 38.3]	<0.001
Moderate	181 (42.2) [37.6, 46.9]	12 (10.6) [6.2, 17.7]	169 (53.5) [48.0, 58.9]	<0.001
Severe	0 (0.0)	0 (0.0)	0 (0.0)	-
Critical	1 (0.2) [0.0, 1.3]	0 (0.0)	1 (0.3) [0.1, 1.8]	-

[a] Asymptomatic at discharge denotes being asymptomatic during the entire hospital stay.

[b] p values were calculated by or Fisher's exact test.

Table 4. Multivariable logistic regression with illness severity or discharge diagnosis as dependent variable stratified by age

	Illness severity on admission (moderate vs mild)			Discharge diagnosis (moderate vs mild)		
	Overall (n=429)	Children (n=113)	Adults (n=316)	Overall (n=429)	Children (n=113)	Adults (n=316)
	aOR (95%CI)	aOR (95%CI)	aOR (95%CI)	OR (95%CI)	OR (95%CI)	OR (95%CI)
Age		1.10 (0.80, 1.54)	1.04 (1.02, 1.06)		1.15 (0.85, 1.60)	1.05 (1.02, 1.07)
<18	ref			ref		
≥ 18 years	4.95 (2.20, 11.97)			7.95 (3.68, 18.23)		
Sex						
Female	ref	ref	ref	ref	ref	ref
Male	0.84 (0.51, 1.37)	1.66 (0.40, 6.96)	0.84 (0.49, 1.43)	0.89 (0.53, 1.48)	2.68 (0.72, 11.01)	0.81 (0.45, 1.46)
BMI, kg/m^2	0.98 (0.93, 1.03)	0.82 (0.63, 1.01)	1.02 (0.95, 1.08)	1.03 (0.97, 1.09)	0.82 (0.64, 0.99)	1.08 (1.01, 1.16)
Vaccination status						
Unvaccinated or partially vaccinated	ref	ref	ref	ref	ref	ref
Fully vaccinated	0.79 (0.37, 1.73)	0.68 (0.06 9.27)	0.90 (0.37, 2.22)	0.76 (0.33, 1.74)	0.63 (0.06, 7.97)	0.76 (0.27, 2.04)

	aOR	(95% CI)		aOR	(95% CI)	aOR	(95% CI)		aOR	(95% CI)
Booster vaccinated	1.21	(0.56, 2.68)	n.a	1.47	(0.62, 3.57)	0.61	(0.26, 1.41)	n.a	0.65	(0.23, 1.70)
Current or former smoker	1.47	(0.67, 3.23)	n.a	1.23	(0.55, 2.77)	1.25	(0.55, 2.97)	n.a	1.03	(0.44, 2.53)
Comorbidities										
Cardiovascular disease	1.15	(0.63, 2.10)	n.a	0.56	(0.27, 1.15)	2.51	(1.31, 5.01)	n.a	1.07	(0.48, 2.40)
Diabetes	2.39	(0.96, 6.28)	n.a	2.19	(0.84, 6.14)	0.76	(0.27, 2.17)	n.a	0.59	(0.21, 1.78)

Abbreviations: aOR, adjusted odds ratio; ref, reference; n.a, not available.

Table 5. Multivariable linear regression with course-related intervals of the Omicron variant as dependent variable stratified by age

	Interval of reversing positive PCR-test into negative						Interval from hospital admission to the aggravation of Covid-19 symptoms					
	Overall (n=429)		Children (n=113)		Adults (n=316)		Overall (n=429)		Children (n=113)		Adults (n=316)	
	aβ	(95%CI)	aβ	(95%CI)	aβ	(95%CI)	aβ	(95%CI)	aβ	(95%CI)	aβ	(95%CI)
Age			0.26	(-0.06, 0.58)	0.00	(-0.04, 0.03)			0.11	(-0.31, 0.54)	0.00	(-0.03, 0.04)
<18	ref						ref					
≥ 18 years	0.87	(-0.21, 1.96)					-0.32	(-1.51, 0.86)				
Sex												
Female	ref		ref		ref		ref		ref		ref	
Male	0.44	(-0.31, 1.19)	1.22	(-0.30, 2.75)	0.18	(-0.67, 1.03)	0.02	(-0.75, 0.79)	0.50	(-1.31, 2.31)	-0.22	(-1.13, 0.68)
BMI, kg/m^2	0.03	(-0.05, 0.11)	-0.09	(-0.29, 0.10)	0.03	(-0.06, 0.13)	0.06	(-0.02, 0.14)	-0.02	(-0.34, 0.29)	0.07	(-0.02, 0.16)
Illness severity on admission												
Mild	ref		ref		ref		ref		ref		ref	
Moderate	-0.13	(-0.91, 0.65)	-0.12	(-2.30, 2.06)	0.05	(-0.82, 0.92)	0.48	(-0.33, 1.28)	2.72	(0.11, 5.32)	-0.37	(-1.32, 0.58)

Vaccination status

Unvaccinated or partially

	aβ	(95% CI)		aβ	(95% CI)		aβ	(95% CI)		aβ	(95% CI)		aβ	(95% CI)		aβ	(95% CI)	
Unvaccinated or partially	ref			ref			ref			ref			ref			ref		
Fully vaccinated	-1.14	(-2.32,	0.04)	-2.82	(-5.64,	0.00)	-1.12	(-2.54,	0.29)	0.24	(-0.93,	1.41)	0.59	(-3.02,	4.21)	0.33	(-1.05,	1.70)
Booster vaccinated	-1.62	(-2.88,	-0.35)	-3.06	(-10.32,	4.19)	-1.59	(-2.99,	-0.20)	-0.36	(-1.59,	0.88)	n.a.			-0.20	(-1.60,	1.20)
Current or former smoker	-0.07	(-1.35,	1.21)	n.a.			0.25	(-1.01,	1.51)	-1.01	(-2.32,	0.31)	n.a.			-1.14	(-2.45,	0.17)
Comorbidities																		
Cardiovascular disease	0.98	(0.00,	1.97)	3.61	(-1.55,	8.77)	0.92	(-0.19,	2.03)	0.49	(-0.45,	1.43)	n.a.			0.53	(-0.60,	1.65)
Diabetes	-0.03	(-1.54,	1.48)	2.24	(-4.80,	9.28)	-0.28	(-1.81,	1.24)	0.69	(-0.75,	2.13)	n.a.			0.52	(-0.94,	1.97)

Abbreviations: aβ, adjusted β-coefficient; ref, reference; n.a, not available.

Table 6. Multivariable logistic regression with aggravation of symptoms of the Omicron variant during hospital stay as dependent variable stratified by age

	Overall (n=429)		Children (n=113)		Adults (n=316)	
	aOR	(95%CI)	OR	(95%CI)	OR	(95%CI)
Age			1.16	(0.96, 1.43)	1.00	(0.98, 1.02)
<18	ref					
≥ 18 years	1.09	(0.56, 2.14)				
Sex						
Female	ref		ref		ref	
Male	1.20	(0.76, 1.90)	1.52	(0.60, 3.97)	1.17	(0.68, 1.99)
BMI, kg/m²	1.03	(0.98, 1.08)	0.91	(0.79, 1.03)	1.06	(1.00, 1.13)
Illness severity on admission						
Mild	ref		ref		ref	
Moderate	0.66	(0.40, 1.06)	1.49	(0.37, 6.07)	0.54	(0.31, 0.92)
Vaccination status						
Unvaccinated or partially vaccinated	ref		ref		ref	
Fully vaccinated	0.83	(0.41, 1.68)	0.58	(0.10, 3.16)	0.73	(0.31, 1.75)
Booster vaccinated	0.65	(0.31, 1.36)	n.a.		0.61	(0.26, 1.43)
Current or former smoker	0.79	(0.35, 1.75)	n.a.		0.79	(0.34, 1.79)
Comorbidities						
Cardiovascular disease	2.35	(1.30, 4.30)	n.a.		2.18	(1.07, 4.52)

Diabetes	1.13	(0.45,	2.86)	n.a.		1.22	(0.46, 3.21)

Abbreviations: aOR, adjusted odds ratio; ref, reference; n.a, not available.

Figure Legend

Figure 1 Flow chart of patient screening and information collection

Figure 2 Course intervals of the SARS-CoV-2 Omicron infection in asymptomatic, presymptomatic, mild and moderate subject, stratified by age.

The numbers in x-axis are days. The grids are filled with median and interquartile range. Dark color denotes medians and light color denotes the IQRs. Patient with severe disease (n=1) was excluded.

Figure 1. Flow chart of patient screening and information collection

Figure 2 Course intervals of the SARS-CoV-2 Omicron infection in asymptomatic, presymptomatic, mild and moderate subject, stratified by age.

The numbers in x-axis are days. The grids are filled with median and interquartile range. Dark color denotes medians and light color denotes the IQRs. Patients

with severe disease (n=1) was excluded.